

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

September 19, 2019
Truman Bldg, 301 High Street
Conference Room 490-492,
Jefferson City, MO

Committee Members Present

Conrad Balcer, DO
Jennifer Kemp-Oestreich, Pharm D
Laura Kingsley, Pharm D
Pat Bryant, Pharm D
Angeline Stanislaus, DMH

Jennifer Colozza, Conduent
Megan Fast, Conduent
Olivia Push, Conduent
Janelle Sheen, Conduent
Crystal Wickers, Conduent

Rob Kilo, Biogen
Kim Moore, GLO
Aaron Shaw, Boehringer Ingelheim
Brent Young, GBT
Brian Strickland, Gilead
Michele Shinen, Indivior
Tom Geyer, Lilly
Michaela Newell, MPA
Chrissy Maycock, MU Healthcare
Casady Lilly, MU Healthcare
Terry Mccarren, Otsuka
Donna Osterland, Sanoti Genzene
Melissa Duvall, Sobi
Dann Piplen, Sorepta
Paige Curtis, SSM-Audrain Intern
Lauren Rackerson, St Louis University
Heather Maniska, United Healthcare
Amy Heidenreich, United Therapeutics
Doug Wood, Viiv Healthcare

MO HealthNet Staff Present:

Josh Moore, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Elizabeth Sissom, RN, Clinical Management
Angela Wilson, Pharmacy Operations
Manager
Beth Mitchell, Administrative Assistant
Dr. Timothy Kling, MD, Assistant Medical
Director
Lisa E. Smith, Program Development
Specialist
Jackie Hickman, Drug Rebate Unit Supervisor
Connie Sutter, Fiscal Manager
Elizabeth Short, Program Specialist

Geri Roling, Wipro
Chelsea Pendleton, Wipro

Others Attending:

Michael Lafend, Abbvie
Roxann Domomguez, Abbvie
Audrey Rattan, Alkermes
Evan Rushing, Alkermes
Jennifer Sabath, Allergan
Camille Kerr, Amgen
Janene Verrant, AstaZeneca
Lydia Shenoudia, Avexis
Kim Witte, Avexis
Rancy McGinlay, Bayer
K Rosa, Biocodex
Tami Sova, Biogen

Contractors in Attendance:

Luke Boehmer, Conduent

| | |
|---|---|
| Welcome, Introductions and Opening Remarks | Conrad Balcer, Chair, called the meeting to order. Josh Moore introduced himself and started the introductions and opening remarks. |
| Minutes Approval | Minutes of the June 2019 Drug PA meeting were reviewed and approved. Pat Bryant made the motion and Laura Kingsley seconded the motion. |
| Pharmacy Program/Budget Update | Elizabeth Short presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking. |
| Old Business | |
| Old Business Implementation Schedule | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included June/July, 2019 PDL decisions to be implemented October 3, 2019. Schedules may be found on the MHD web page at https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf |
| MS Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. Recommendations from the Rare Disease Advisory Committee. ● Public Hearing –Evie Knisely spoke about Mayzent. Tami Sova spoke on Tecfidera. ● Decision – The Committee voted to accept this Clinical Edit as recommended. (See Roll Call Vote) |
| New Business | |
| New Drug Review | <p>Josh Moore reviewed the new products identified for the quarter June 2019 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> ● Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. ● Public Hearing –Lydia Shenouda spoke on Zolgensma, Roxann Dominguez spoke on Skyrizi. ● Decision – Members voted to accept the new product recommendations as presented |
| Clinical Edits | |
| BiDiI Clinical Editt | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing –No Public Comment ● Decision – The Committee voted to accept this Clinical Edit with changes. (See Roll Call Vote) |

| | |
|--|---|
| Botulinum Toxin Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – Mark Frederich commented on criteria ● Decision – The Committee voted to accept this Clinical Edit with changes. (See Roll Call Vote) |
| Diacomit Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – Keith Rose commented on Diacomit. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote) |
| Duchenne Muscular Dystrophy (DMD) Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No public comment ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote) |
| Emsam Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to revisit after website has been updated. (See Roll Call Vote) |
| Lambert-Eaton Myasthenic Syndrome(LEMS) Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote) |
| Narcolepsy Inhibitors Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote) |
| Oxandrin Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Psychotropic Medications Polypharmacy Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Ranexa Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| SNRI Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| SSRI Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Synagis Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Mark Roseau reviewed the new criteria in this document. |

| | |
|--|--|
| | <ul style="list-style-type: none"> ● Public Hearing –No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing –Andrew Hsieh spoke on Tegsedi ● Decision – The Committee voted to accept this Clinical Edit with recommended change. (See Roll Call Vote) |
| Zolgensma Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing - Lydia Shenouda spoke on Zolgensma ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Zometa Clinical Edit | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria in this document. ● Public Hearing – No Public Comment ● Decision – The Committee voted to accept this Clinical Edit. (See Roll Call Vote) |
| Preferred Drug List (PDL) | |
| ACE Inhibitors/Calcium Channel Blocker Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred. ● Public Hearing – No Comments Entered ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ADHD – Amphetamines – Short Acting Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ADHD – Methylphenidate – Long Acting Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ADHD – Methylphenidate – Short Acting Agents | <ul style="list-style-type: none"> ● Discussion –Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |

| | |
|--|---|
| ADHD – Amphetamines – Long Acting Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ADHD – Non-stimulant Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| ARB and ARB Diuretic Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No Public Comments ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Angiotensin II Receptor/Calcium Channel Blocker Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No Comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Anticoagulant Agents: Oral and Subcutaneous) | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. Stated there are no changes recommended for this class. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Antiplatelet Agents | <ul style="list-style-type: none"> ● Discussion – Mr. Roaseau stated there are no changes recommended for this class. ● Public Hearing – Janene Verrant spoke on Brilinta ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Beta Adrenergic Blocker and Beta Adrenergic Blocker Diuretic Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Calcium Channel Blocker Agents (Dihydropyridines) | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No Public Comments ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Calcium Channel Blocker Agents (Non-Dihydropyridines) | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |

| | |
|---|---|
| Direct Renin Inhibitors and Direct Renin Inhibitors Combination Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Dry Eye Disease Agents - NEW | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Lipotropic Agents: Niacin Derivatives | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Lipotropic Agents: Triglyceride Lowering Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Proton Pump Inhibitor Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit with recommended changes. (See Roll Call Vote) |

| | |
|---|---|
| Pulmonary Arterial Hypertension (PAH) Agents: Inhaled/Injectable | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Pulmonary Arterial Hypertension (PAH) Agents: Oral Endothelin Receptor Antagonists (ETRAAs) | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Pulmonary Arterial Hypertension (PAH) Agents: Oral Phosphodiesterase-5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (SCG) Stimulators | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Pulmonary Arterial Hypertension (PAH) Agents: Oral Prostacyclin Pathway Agonists | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – Amy Heidenreich spoke on Orenitram. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Sympatholytic Antihypertensive Agents | <ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments were entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| Preferred Drug List Announcement | <p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page:</p> <p>http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</p> |
| | |
| Conduent Update | <p>Conduent did present the following items for review. These items were included in the packet for the meeting. Here is the list:</p> <ul style="list-style-type: none"> • Helpdesk Status Report • User Statistics • New Drug Summary. |

| | |
|--|--|
| Program Utilization: Top 25 Drugs Summary | The Top 25 Drugs Summary Reports for the 4 quarters of fiscal year 2019 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims. |
| Adjourn | The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the Drug Prior Authorization Committee is scheduled for December 19, 2019 at the Missouri Coalition for Community Behavioral Healthcare Building, Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO. |

ROLL CALL FOR DRUG PA SEPTEMBER 19, 2019

| <u>Member</u> | Minutes | New Drugs | Old Business-MS Agents | BiDiI CE | Botulinum Toxin Clinical Edit | Diacomit CE |
|----------------------------------|---------|-----------|------------------------|----------|-------------------------------|-------------|
| Conrad Balcer, D.O. | A | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | MY | MY | SY | Y | MY | SY |
| Angeline Stanislaus | Y | Y | Y | Y | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | Y | Y | MY | SY | Y | Y |
| Laura Kingsley, Pharm D | SY | SY | Y | MY | SY | MY |

| | | | | | | |
|----------------------------------|---|-----------------|--|---------------------------------|---|---|
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |
| | | | | | | |
| Member | Duchenne Muscular Dystrophy (DMD) CE | Emsam CE | Lambert-Eaton Myasthenic Syndrome(LEMS)CE | Narcolepsy Inhibitors CE | Oxandrin CE | Psychotropic Medications Polypharmacy CE |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | SY | MY | Y | MY | MY | SY |
| Angeline Stanislaus | Y | Y | Y | Y | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | Y | SY | MY | Y | Y | MY |
| Laura Kingsley, Pharm D | MY | Y | SY | SY | SY | Y |
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | | | | | | |
| Member | Ranexa CE | SNRI CE | SSRI CE | Synagis CE | Transthyretin-Mediated Amyloidosis (ATTR) CE | Zolgensma CE |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | Y | MY | Y | MY | MY | SY |
| Angeline Stanislaus | Y | Y | Y | SY | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | MY | SY | SY | Y | Y | Y |
| Laura Kingsley, Pharm D | SY | Y | MY | Y | SY | MY |
| Matthew Stinson, MD | A | A | A | A | A | A |

| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |
|---|---|--|--|---|--|---|
| Member | Zometa CE | ACE Inhibitors/Calcium Channel Blocker Combination Agents | ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents | ADHD – Amphetamines – Short Acting Agents | ADHD – Methylphenidate – Long Acting Agents | ADHD – Methylphenidate – Short Acting Agents |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | SY | Y | MY | Y | MY | SY |
| Angeline Stanislaus | Y | SY | Y | SY | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | MY | A | A | A | A | A |
| Laura Kingsley, Pharm D | Y | MY | SY | MY | SY | MY |
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |
| Member | ADHD – Amphetamines – Long Acting Agents | ADHD – Non-stimulant Agents | ARB and ARB Diuretic Combination Agents | Angiotensin II Receptor/Calcium Channel Blocker Como | Anticoagulant Agents: Oral and Subcutaneous | Antiplatelet Agents |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | MY | Y | MY | SY | MY | Y |
| Angeline Stanislaus | SY | SY | SY | Y | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | N | A | A | A | A | A |
| Laura Kingsley, Pharm D | Y | MY | Y | MY | SY | Y |
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |

| <u>Member</u> | Beta Adrenergic Blocker and Beta Adrenergic Blocker Diuretic Combo | Calcium Channel Blocker Agents (Dihydropyridines) | Calcium Channel Blocker Agents (Non-Dihydropyridines) | Direct Renin Inhibitors and Direct Renin Inhibitors Combo | Dry Eye Disease Agents - NEW | Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products |
|----------------------------------|--|--|--|---|------------------------------|--|
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | MY | SY | MY | Y | MY | Y |
| Angeline Stanislaus | SY | Y | SY | SY | Y | SY |
| Jennifer Kemp-Oestreich, Pharm D | A | A | A | A | A | A |
| Laura Kingsley, Pharm D | Y | MY | Y | MY | SY | MY |
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |
| <u>Member</u> | Lipotropic Agents: Niacin Derivatives | Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 | Lipotropic Agents: Statins (HMG Co-A Reductase Inh) and SCPE | Lipotropic Agents: Triglyceride Lowering Agents | Proton Pump Inhibitor Agents | Pulmonary Arterial Hypertension (PHA) Agents: Inhaled/Injectable |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | MY | MY | MY | MY | SY | MY |
| Angeline Stanislaus | SY | SY | SY | SY | Y | Y |
| Jennifer Kemp-Oestreich, Pharm D | A | A | A | A | A | A |
| Laura Kingsley, Pharm D | Y | Y | Y | Y | MY | SY |
| Matthew Stinson, MD | A | A | A | A | A | A |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |

| <u>Member</u> | Pulmonary Arterial Hypertension (PHA) Agents: Oral Endothelin Receptor Antagonists (ETRAAs) | Pulmonary Arterial Hypertension (PHA) Agents: Oral Phosphodiesterase-5 (PDE5) Inhibitors and SGC Stimulators | Pulmonary Arterial Hypertension (PHA) Agents: Oral Prostacyclin Pathway Agonists | Sympatholytic Antihypertensive Agents | Executive meeting | Meeting Adjourn |
|----------------------------------|--|---|---|---------------------------------------|-------------------|-----------------|
| Conrad Balcer, DO | SY | Y | Y | Y | Y | |
| Pat Bryant, Pharm D | MY | SY | MY | MY | MY | |
| Angeline Stanislaus | SY | Y | SY | SY | SY | |
| Jennifer Kemp-Oestreich, Pharm D | A | A | A | A | A | |
| Laura Kingsley, Pharm D | Y | MY | Y | Y | Y | |
| Matthew Stinson, MD | A | A | SY | A | A | |
| Morgan Sperry, Pharm D-Alternate | ALT | | | | | |

Roll Call Abbreviations:**A-Absent****AL-Alternate****R-Ratify****M-Motion****S-Second****Y-Yes to the vote**